Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers

Abstract

Background:

Recent studies have suggested therapeutic benefits of psychedelics for a variety of mental health conditions. The understanding of how single psychedelic administrations can induce long-lasting effects are, in large, still lacking. However, recent studies in both healthy and clinical populations suggest a role for personality changes.

Aim:

To test support for some of these plausible mechanisms we evaluated (cross-sectional) associations between recreational use of psychedelics and 3,4-methylene-dioxymethamphetamine (MDMA) and (a) personality measures and (b) key markers of cerebral serotonergic signalling (serotonin transporter and serotonin-2A-receptor binding).

Methods:

In 10 psychedelic-preferring recreational users, 14 MDMA-preferring users and 21 non-using controls, personality was assessed using the ‘big five‘ instrument Revised NEO Personality Inventory (NEO-PI-R). Frontal serotonin transporter and serotonin-2A-receptor binding potentials were quantified using [¹¹C]DASB and [¹⁸F]altanserin positron emission tomography, respectively.

Results:

Of the five NEO-PI-R traits, only openness to experience scores differed between the three groups; psychedelic-preferring recreational users showing higher openness to experience scores when compared with both MDMA-preferring users and controls. Openness to experience scores were positively associated with lifetime number of psychedelic exposures, and among all MDMA-preferring user/psychedelic-preferring recreational user individuals, frontal serotonin transporter binding – but not frontal serotonin-2A-receptor binding – was positively associated with openness to experience.

Conclusion:

Our findings from this cross-sectional study support increasing evidence of a positive association between psychedelic experiences and openness to experience, and (a) expands this to the context of ‘recreational’ psychedelics use, and (b) links serotonergic neurotransmission to openness to experience. A modulation of personality induced by psychedelic experiences may have important therapeutic implications via its impact on peoples’ value systems, cognitive flexibility, and individual and social behaviour.

Keywords

Openness psychedelics 3,4-methylene-dioxymethamphetamine serotonin serotonin transporter

Get full access to this article

View all access options for this article.

References

Barbosa

Strassman

da Silveira

, et al. (2016) Psychological and neuropsychological assessment of regular hoasca users. Compr Psychiatry 71: 95–105.

Battaglia

Brooks

Kulsakdinun

, et al. (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159–163.

Boulougouris

Tsaltas

(2008) Serotonergic and dopaminergic modulation of attentional processes. Prog Brain Res 172: 517–542.

Buckholtz

Zhou

Freedman

(1988) Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors. Life Sci 42: 2439–2445.

Carhart-Harris

Erritzoe

Haijen

, et al. (2018) Psychedelics and connectedness. Psychopharmacology (Berl). 235: 547–550.

Carhart-Harris

Goodwin

(2017) The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology 42: 2105–2113.

Carhart-Harris

Nutt

(2017) Serotonin and brain function: A tale of two receptors. J Psychopharmacol 31: 1091–1120.

Carney

Jost

Gosling

, et al. (2008) The secret lives of liberals and conservatives: Personality profiles, interaction styles, and the things they leave behind. Political Psychol 29: 807–840.

Costa

McCrae

(1992) NEO Personality Inventory (NEO-PI-R) and NEO Five Factor Inventory (NEO-FFI) Professional Manual. Odessa, FL: Psychological Assessment Resources.

10.

Costa

Jr Bagby

Herbst

, et al. (2005) Personality self-reports are concurrently reliable and valid during acute depressive episodes. J Affect Disord 89: 45–55.

11.

El-Seedi

De Smet

Beck

, et al. (2005) Prehistoric peyote use: Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol 101: 238–242.

12.

Erritzoe

Frokjaer

Haahr

, et al. (2010) Cerebral serotonin transporter binding is inversely related to body mass index. Neuroimage 52: 284–289.

13.

Erritzoe

Frokjaer

Holst

, et al. (2011) In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy‘) and hallucinogen users. Arch Gen Psychiatry 68: 562–576.

14.

Erritzoe

Richards

(2017) Lessons to be learned from early psychedelic therapy in Denmark. Nord J Psychiatry 71: 487–488.

15.

Erritzoe

Roseman

Nour

, et al. (2018) Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand 138: 368–378.

16.

Forstmann

Sagioglou

(2017) Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. J Psychopharmacol 31: 975–988.

17.

Frecska

Móré

Vargha

, et al. (2012) Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. J Psychoactive Drugs 44: 191–199.

18.

Frokjaer

Erritzoe

Holst

, et al. (2014) In abstinent MDMA users the cortisol awakening response is off-set but associated with prefrontal serotonin transporter binding as in non-users. Int J Neuropsychopharmacol 17: 1119–1128.

19.

Furr

Lapiz-Bluhm

Morilak

(2012) 5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats. Int J Neuropsychopharmacol 15: 1295–1305.

20.

Hallock

Dean

Knecht

, et al. (2013) A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. Drug Alcohol Depend 130: 245–248.

21.

Hansen

Mortensen

(2004) Dokumentation for den danske udgave af NEO PI-R og NEO PI-R Kort Version. In: Hansen

Mortensen

Schiøtz

(eds) NEO-PI-R, Manual - Klinisk, 1 ed. Copenhagen, Denmark: Dansk Psykologisk Forlag.

22.

Harman

McKim

Mogar

, et al. (1966) Psychedelic agents in creative problem-solving: A pilot study. Psychol Rep 19: 211–227.

23.

Hartogsohn

(2016) Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30: 1259–1267.

24.

Holst

Budtz-Jørgensen

(2013) Linear latent variable models: The lava-package. Computational Statistics 28: 1385–1452.

25.

Janiger

Dobkin de Rios

(1989) LSD and creativity. J Psychoactive Drugs 21: 129–134.

26.

Johnson

Richards

Griffiths

(2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol 22: 603–620.

27.

Kaufman

Quilty

Grazioplene

, et al. (2016) Openness to experience and intellect differentially predict creative achievement in the arts and sciences. J Pers 84: 248–258.

28.

King

Martin

Melville

(1974) Reversal learning enhanced by lysergic acid diethylamide (LSD): Concomitant rise in brain 5-hydroxytryptamine levels. Br J Pharmacol 52: 419–426.

29.

Kotov

Gamez

Schmidt

, et al. (2010) Linking ‘big‘ personality traits to anxiety, depressive, and substance use disorders: A meta-analysis. Psychol Bull 136: 768–821.

30.

Kuypers

Riba

de la Fuente Revenga

, et al. (2016) Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology (Berl) 233: 3395–3403.

31.

Lebedev

Kaelen

Lovden

, et al. (2016) LSD-induced entropic brain activity predicts subsequent personality change. Hum Brain Mapp 37: 3203–3213.

32.

Lerner

Lyvers

(2006) Values and beliefs of psychedelic drug users: A cross-cultural study. J Psychoactive Drugs 38: 143–147.

33.

Licht

Christoffersen

Okholm

, et al. (2012) Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: Combination patterns and proposed biological bases. Hum Psychopharmacol 27: 352–363.

34.

Lyons

Carhart-Harris

(2018) Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol 32: 811–819.

35.

MacKinnon

Lockwood

Hoffman

, et al. (2002) A comparison of methods to test mediation and other intervening variable effects. Psychol Methods 7: 83–104.

36.

MacLean

Johnson

Griffiths

(2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461.

37.

McCrae

(1987) Creativity, divergent think and openness to experience. J Pers Soc Psychol 52: 1258–1265.

38.

McCrae

John

(1992) An introduction to the five-factor model and its applications. J Pers 60: 175–215.

39.

McGlothlin

Cohen

McGlothlin

(1967) Long lasting effects of LSD on normals. Arch Gen Psychiatry 17: 521–532.

40.

McGlothlin

Arnold

(1971) LSD revisited. A ten-year follow-up of medical LSD use. Arch Gen Psychiatry 24: 35–49.

41.

Mithoefer

Wagner

Mithoefer

, et al. (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. J Psychopharmacol 27: 28–39.

42.

Nichols

(2004) Hallucinogens. Pharmacol Ther 101: 131–181.

43.

Nichols

(2016) Psychedelics. Pharmacol Rev 68: 264–355.

44.

Nour

Evans

Carhart-Harris

(2017) Psychedelics, personality and political perspectives. J Psychoactive Drugs 49: 182–191.

45.

Pinborg

Adams

Svarer

, et al. (2003) Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab 23: 985–996.

46.

Schifano

Corkery

Deluca

, et al. (2006) Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003). J Psychopharmacol 20: 456–463.

47.

Sibley

Osborne

Duckitt

(2012) Personality and political orientation: Meta-analysis and test of a threat-constraint model. J Res Pers 46: 664–677.

48.

Smit

Moore

Measham

(2009) MDMA powder, pills and crystal: The persistence of ecstasy and the poverty of policy. Drugs Alcohol Today 9: 13–19.

49.

St John Sessa

(2008) Are psychedelic drug treatments seeing a comeback in psychiatry? Prog Neurol Psychiatry 12: 5–10.

50.

Svarer

Madsen

Hasselbalch

, et al. (2005) MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 24: 969–979.

51.

Terracciano

McCrae

Brant

, et al. (2005) Hierarchical linear modeling analyses of the NEO-PI-R scales in the Baltimore Longitudinal Study of Aging. Psychol Aging 20: 493–506.

52.

Vollenweider

Vollenweider-Scherpenhuyzen

Babler

, et al. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9: 3897–3902.

53.

Wagner

Mithoefer

, et al. (2017) Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. J Psychopharmacol 31: 967–974.

54.

Mar

Peterson

(2013) Does cultural exposure partially explain the association between personality and political orientation? Pers Soc Psychol Bull 39: 1497–1517.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.88 MB